Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers

1. A flexible, readily adhesive, non-sticky, cosmetically inconspicuous patch for dermal or transdermal administration of an active ingredient, said patch comprising:

a transparent, clear film that can be obtained by:

applying on a patient's skin a pharmaceutical preparation, wherein said pharmaceutical preparation is in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.01-30% (w/w) of one or more active ingredients;

0.01-20% (w/w) of one or more softeners;

32-99.7% (w/w) ethanol as solvent;

up to 50% (w/w) water; and

subsequently evaporating said solvent, whereby no recrystallization of the active ingredient occurs and the active ingredient is present in dissolved form in the patch;

wherein said patch has a wearing time of at least 24 hours.

2. A patch according to claim 1 , wherein said patch has a water vapor permeability above 0.05 g*cm −2 *24 −1 .

3. A patch according to claim 1 , the amount of polyurethane-14-AMP-acrylate copolymer in said pharmaceutical preparation is 5-30% (w/w).

4. A patch according to claim 1 , wherein said pharmaceutical preparation comprises:

optionally 0.01-10% (w/w) of one or more moisturizers,

optionally 0.01-10% (w/w) of one or more emulsifiers, and/or

optionally 0.01-15% (w/w) of one or more permeation enhancers.

5. A patch according to claim 1 , wherein said pharmaceutical preparation comprises:

0.01-10% (w/w) of one or more moisturizers,

0.01-10% (w/w) of one or more emulsifiers, and/or

0.01-15% (w/w) of one or more permeation enhancers.

6. A patch according to claim 4 , wherein said pharmaceutical preparation is in the form of a solution, emulsion or suspension.

7. A patch according to claim 4 , wherein said patch is adapted to provide transdermal administration of said one or more active ingredient.

8. A patch according to claim 7 , wherein said one or more active ingredients are selected from:

Testosterone and esters of testosterone, testosterone dipropionate, 7-methyl-11-fluoro-19-nortestosterone, and 7-methyl-19-nortestosterone;

ethinyl estradiol, mestranol, quinestranol, estradiol, estrone, estrane, estriol, estetrol, and conjugated equine estrogens;

progesterone, hydroprogesterone caproate, levonorgestrel, norgestimate, norethisterone, drospirenone, dydrogesterone, norelgestromin, levonorgestrel, dienogest, danazol, lynestrenol, etonogestrel, medrogestone, nestorone, and cyproterone acetate;

finasteride, nicotine, nitroglycerin, fentanyl, clonidine, isosorbide dinitrate, rotigotine, and oxybutynin;

and pharmaceutically acceptable salts thereof.

9. A patch according to claim 8 , wherein said one or more active ingredients are selected from: testosterone, testosterone dipropionate, 7-methyl11-fluoro-19-nortestosterone, 7-methyl-19-nortestosterone, and pharmaceutically acceptable salts thereof.

10. A patch according to claim 4 , wherein said patch is adapted to provide dermal administration of said one or more active ingredients.

11. A patch according to claim 10 , wherein said one or more active ingredients are selected from:

clindamycin, kanamycin, gentamycin, metronidazole, tyrothricin, bacitracin, and mupirocin;

ketoconazole, itraconazole, amphotericin B, griseofulvin, fluconazole, amorolfine, flucytosine, terbinafine, naftifine, ciclopirox, natamycin, nystatin, undecenoic acid, and isoconazole;

methylprednisolone aceponate, clobetasol propionate, mometasone fuorate, hydrocortisone, betamethasone-17-benzoate, prednicarbate, diflucortolone valerate, triamcinilone acetonide, amcinonide, desoxymethasone, fluocortolone, and fluticasone;

tacrolimus and pimecrolimus;

azelastine, fexofenadine, levocabastine, loratadine, mizolastine, clemastine, bamipine, cetirizine, dimetidine, ketotifen, and emedastine;

tretinoin, isotretinoin, acitretin, adapalene, and tazarotene;

diclofenac-Na and salts thereof, aciclovir, penciclovir, idoxuridine, trifluridine, vidarabine, tromantadine, lidocaine, procaine, and cinchocaine;

and pharmaceutically acceptable salts thereof.

12. A patch according to claim 1 , wherein said one or more softeners are selected from:

Triethyl citrate,

Tributyl citrate,

Acetyl triethyl citrate,

Acetyl tributyl citrate,

Triacetin,

Dibutyl phthalate,

Dibutyl sebacate,

Diethyl phthalate,

Propylene glycol,

Polyethylene glycol,

Glycerol, and

Castor oil.

13. A patch according to claim 4 , wherein said pharmaceutical preparation contains one or more moisturizers selected from: glycerol, sorbitol, propylene glycol, polyethylene glycol, and polyvinyl pyrrolidone.

14. A patch according to claim 4 , wherein said pharmaceutical preparation contains one or more emulsifiers selected from: Na-lauryl sulfate, Na-cetyl stearyl sulfate, glycerol fatty acid ester, lecithin, fatty alcohols, cholesterol, sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene fatty acid glycerides, and polyoxyethylene fatty alcohol ether.

15. A patch according to claim 4 , wherein said pharmaceutical preparation contains one or more permeation enhancers selected from: laurocaprams, sulfoxides, terpenes, ethereal oil, oleic acid, oleyl alcohol, lauryl acid, propylene glycol, propylene carbonate, N-methyl-pyrrolidone, and isopropyl myristate.

16. A patch according to claim 4 , wherein said pharmaceutical preparation contains one or more permeation enhancers selected from: oleic acid, R-(+)-limonene, isopropyl myristate, mono-isopropyl myristate, a combination of oleic acid with propylene glycol, a combination of R-(+)-limonene with propylene glycol, or a combination of isopropyl myristate with propylene glycol.

17. A patch according to claim 4 wherein said pharmaceutical further contains a propellant.

18. A kit for applying a film-forming pharmaceutical preparation, said kit comprising:

a roller, a pump sprayer, a sprayer, a tube, a brush bottle or a pipette bottle; and

a pharmaceutical preparation in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.01-30% (w/w) of one or more active ingredients;

a mixture of ethanol and isopropanol;

up to 50% (w/w) water; and

0.01-20% (w/w) of one or more softeners;

wherein said preparation has a wearing time of at least 24 hours.

19. A kit according to claim 18 , wherein the amount of said polyurethane-14-AMP-acrylate copolymer is 5-30% by weight of preparation.

20. A patch according to claim 1 , wherein said active ingredient is ethinyl estradiol or levonorgestrel.

21. A patch according to claim 1 , wherein said pharmaceutical preparation consists essentially of: said polyurethane-14-AMP-acrylate copolymer, said one or more active ingredients, said ethanol as solvent, said one or more softeners, optionally water, optionally one or more moisturizers, optionally one or more emulsifiers, and optionally one or more permeation enhancers.

22. A patch according to claim 1 , wherein said pharmaceutical preparation consists of: said polyurethane-14-AMP-acrylate copolymer, said one or more active ingredients, said ethanol as solvent, said one or more softeners, optionally water, optionally one or more moisturizers, optionally one or more emulsifiers, and optionally one or more permeation enhancers.

23. A patch according to claim 1 , wherein said pharmaceutical preparation comprises: 0.1-40% (w/w) polyurethane-14-AMP-acrylate copolymer; 0.1-18% (w/w) triethyl citrate; 0.1-50% (w/w) water; said ethanol as solvent, and 0.1-30% (w/w) active ingredient.

24. A patch according to claim 23 , wherein said pharmaceutical preparation comprises: 10-40% (w/w) polyurethane-14-AMP-acrylate copolymer; 0.1-18% (w/w) triethyl citrate; 0.1-50% (w/w) water; said ethanol as solvent, and 5-30% (w/w) active ingredient.

25. A patch according to claim 23 , wherein said pharmaceutical preparation comprises: 0.1-40% (w/w) polyurethane-14-AMP-acrylate copolymer; 0.1-18% (w/w) triethyl citrate; 0.1-10% (w/w) of permeation enhancers selected from oleic acid, R-(+)-limonene, isopropyl myristate, propylene glycol, and combinations thereof; 0.1-50% (w/w) water; said ethanol as solvent, and 0.1-30% (w/w) active ingredient.

26. A patch according to claim 1 , wherein said one or more softeners are selected from triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triacetin, dibutyl phthalate, dibutyl sebacate, diethyl phthalate, and castor oil.

27. A patch according to claim 1 , wherein said pharmaceutical preparation comprises polyurethane-14-AMP-acrylate copolymer, triethyl citrate, water, said ethanol as solvent, and active ingredient.

28. A patch according to claim 1 , wherein said pharmaceutical preparation comprises polyurethane-14-AMP-acrylate copolymer, triethyl citrate, water, said ethanol as solvent, active ingredient, and one or more permeation enhancers.

29. A flexible, readily adhesive, non-sticky, cosmetically inconspicuous patch for dermal or transdermal administration of an active ingredient, said patch comprising:

a transparent, clear film that can be obtained by applying on a patient's skin a pharmaceutical preparation, wherein said pharmaceutical preparation is in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.01-30% (w/w) of one or more active ingredients;

0.01-20% (w/w) triethyl citrate as softener;

a mixture of ethanol and isopropanol;

up to 50% (w/w) water; and

subsequently evaporating said solvent, whereby no recrystallization of the active ingredient occurs and the active ingredient is present in dissolved form in the patch;

wherein said patch has a wearing time of at least 24 hours.

30. A flexible, readily adhesive, non-sticky, cosmetically inconspicuous patch for dermal or transdermal administration of an active ingredient, said patch comprising:

a transparent, clear film that can be obtained by applying on a patient's skin a pharmaceutical preparation, wherein said pharmaceutical preparation is in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.01-30% (w/w) of one or more active ingredients;

0.01-20% (w/w) of one or more softeners;

a mixture of ethanol and isopropanol as solvent;

up to 50% (w/w) water; and

subsequently evaporating said solvent, whereby no recrystallization of the active ingredient occurs and the active ingredient is present in dissolved form in the patch;

wherein said patch has a wearing time of at least 24 hours.

31. A flexible, readily adhesive, non-sticky, cosmetically inconspicuous patch for dermal or transdermal administration of an active ingredient, said patch comprising:

a transparent, clear film that can be obtained by applying on a patient's skin a pharmaceutical preparation, wherein said pharmaceutical preparation is in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.01-30% (w/w) of one or more active ingredients;

0.01-18% (w/w) triethyl citrate as softener;

32-99.7% (w/w) ethanol;

up to 50% (w/w) water; and

subsequently evaporating said solvent, whereby no recrystallization of the active ingredient occurs and the active ingredient is present in dissolved form in the patch;

wherein said patch has a wearing time of at least 24 hours.

32. A flexible, readily adhesive, non-sticky, cosmetically inconspicuous patch for dermal or transdermal administration of an active ingredient, said patch comprising:

a transparent, clear film that can be obtained by applying on a patient's skin a pharmaceutical preparation, wherein said pharmaceutical preparation is in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.01-30% (w/w) of one or more active ingredients;

0.01-18% (w/w) triethyl citrate as softener;

a mixture of ethanol and isopropanol as solvent;

up to 50% (w/w) water; and

subsequently evaporating said solvent, whereby no recrystallization of the active ingredient occurs and the active ingredient is present in dissolved form in the patch;

wherein said patch has a wearing time of at least 24 hours.

33. A patch according to claim 1 , wherein said film is dry by 5 minutes after application to said patient's skin.

34. A patch according to claim 29 , wherein said film is dry by 5 minutes after application to said patient's skin.

35. A patch according to claim 30 , wherein said film is dry by 5 minutes after application to said patient's skin.

36. A patch according to claim 31 , wherein said film is dry by 5 minutes after application to said patient's skin.

37. A patch according to claim 32 , wherein said film is dry by 5 minutes after application to said patient's skin.

38. A kit for applying a film-forming pharmaceutical preparation, said kit comprising:

a roller, a pump sprayer, a sprayer, a tube, a brush bottle or a pipette bottle; and

a pharmaceutical preparation in the form of a clear, sprayable solution, said pharmaceutical preparation comprising:

0.1-40% (w/w) of polyurethane-14-AMP-acrylate copolymer;

0.1-30% (w/w) of one or more active ingredients;

0.01-20% (w/w) of one or more softeners;

32-99.7% (w/w) ethanol as solvent; and

up to 50% (w/w) water;

wherein said preparation has a wearing time of at least 24 hours.